Plain-English translation of NCT03562169 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called ixazomib can help improve the results of stem cell transplant treatment for people with multiple myeloma that has come back. Researchers want to see if adding this medication to the standard transplant preparation makes the cancer respond better and stay controlled longer. About 406 patients will be enrolled across multiple hospitals to compare this new approach with standard treatment.
Multiple myeloma often comes back even after stem cell transplant, and patients need better options to keep the cancer under control longer. This trial is testing whether this medication can strengthen the transplant process and help maintain remission after treatment is complete.
You likely qualify if…
You likely don't qualify if…
You will first receive 4 to 6 months of chemotherapy with three drugs (including ixazomib) to prepare your body and get your cancer under control. If your cancer responds well, you will then have a stem cell transplant, where you receive either standard-dose chemotherapy or a modified dose combined with ixazomib before getting your stored stem cells back. After the transplant, you may receive additional treatment cycles or ongoing maintenance therapy depending on which group you're randomly assigned to. Throughout the trial, you'll have frequent blood tests, scans, and clinic visits to monitor your response and manage side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United Kingdom